OSLO, Norway, March 10, 2020 /PRNewswire/ -- Financial calendar
for Nordic Nanovector ASA
FINANCIAL YEAR 2019
27.03.2020 - Annual Report
FINANCIAL YEAR 2020
27.08.2020 - Half-yearly
Report
30.04.2020 - Annual General
Meeting
26.05.2020 - Quarterly Report -
Q1
19.11.2020 - Quarterly Report -
Q3
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains
global marketing rights to Betalutin® and intends to actively
participate in the commercialisation of Betalutin® in the US and
other major markets.
For further information, please contact:
IR
enquiries
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
Media Enquiries
Mark
Swallow/Frazer Hall/David
Dible (Citigate Dewe Rogerson)
Tel: +44-203-926-8535
Email: nordicnanovector@citigatedewerogerson.com
Further information can be found
at www.nordicnanovector.com.
This information is published pursuant to the requirements set
out in the Continuing obligations.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---financial-calendar,c3055792